BG103937A - Производни на 5-нафтален-1-ил-1,3-диоксан, тяхното получаване и използването им в терапията - Google Patents

Производни на 5-нафтален-1-ил-1,3-диоксан, тяхното получаване и използването им в терапията

Info

Publication number
BG103937A
BG103937A BG103937A BG10393799A BG103937A BG 103937 A BG103937 A BG 103937A BG 103937 A BG103937 A BG 103937A BG 10393799 A BG10393799 A BG 10393799A BG 103937 A BG103937 A BG 103937A
Authority
BG
Bulgaria
Prior art keywords
group
optionally substituted
therapy
nitrogen
naphthalen
Prior art date
Application number
BG103937A
Other languages
English (en)
Inventor
Gihad Dargazanli
Patrick Lardenois
Jonathan Frost
Pascal George
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9706945A external-priority patent/FR2764288B1/fr
Priority claimed from FR9706946A external-priority patent/FR2764289B1/fr
Priority claimed from FR9706947A external-priority patent/FR2764291B1/fr
Priority claimed from FR9706944A external-priority patent/FR2764287B1/fr
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of BG103937A publication Critical patent/BG103937A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Изобретението се използва в терапията и се отнасядо съединение с обща формула@@в която R1 означава алкилова група, V означава водороден атом, алкилова група с права или разклонена верига, циклоалкилова група, циклоалкилметилова група, фенилалкилова група, която в даден случай е заместена във фениловия пръстен, карбоксиметилова група, алкоксикарбонилметилова група или карбамоилметилова група, която в даден случай е заместена при азота, W означава карбоксиметилова група, алкоксикарбонилметиловагрупа, карбамоилметилова група, която в даден случай е заместена при азота, 4- до 7-членна пръстенна група, в даден случай съдържаща кислороден или серен атом, пиридилметилова група, 1-метилпиролилметилова група, фуранилметилова група, тиенилметилова група или 1,3-тиазолилметилова група или алтернативно V и W образуват заедно с азотния атом, с който са свързани, пиролидинилова, пиперидилова или 1,2,3,4-тетрахидроизохинолилова група.
BG103937A 1997-06-05 1999-11-30 Производни на 5-нафтален-1-ил-1,3-диоксан, тяхното получаване и използването им в терапията BG103937A (bg)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9706945A FR2764288B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706946A FR2764289B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706947A FR2764291B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706944A FR2764287B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
PCT/FR1998/001113 WO1998055474A1 (fr) 1997-06-05 1998-06-03 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
BG103937A true BG103937A (bg) 2000-07-31

Family

ID=27447000

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103937A BG103937A (bg) 1997-06-05 1999-11-30 Производни на 5-нафтален-1-ил-1,3-диоксан, тяхното получаване и използването им в терапията

Country Status (18)

Country Link
EP (1) EP0986552A1 (bg)
JP (1) JP2002502412A (bg)
KR (1) KR20010013435A (bg)
CN (1) CN1265658A (bg)
AR (1) AR012908A1 (bg)
AU (1) AU8025198A (bg)
BG (1) BG103937A (bg)
BR (1) BR9810742A (bg)
CA (1) CA2290695A1 (bg)
CO (1) CO4940480A1 (bg)
EE (1) EE9900560A (bg)
HU (1) HUP0002166A3 (bg)
IL (1) IL133242A0 (bg)
NO (1) NO995966L (bg)
PL (1) PL337234A1 (bg)
SK (1) SK166199A3 (bg)
TR (1) TR199903022T2 (bg)
WO (1) WO1998055474A1 (bg)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200401511T4 (tr) * 2000-07-21 2004-08-23 Ortho-Mcneil Pharmaceutical, Inc. Nöropatik ağrı ve baş ağrısı nöbetleri ve migren tipi baş ağrısı ile ilişkili ağrının önlenmesi veya tedavi edilmesinde kullanılan karbamat bileşikleri.
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461958B1 (fr) * 1990-06-15 1994-09-14 Synthelabo Dérivés de 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanes, leur préparation et leur application en thérapeutique
FR2714055B1 (fr) * 1993-12-22 1996-01-19 Synthelabo Dérivés de 5-(arylalkyl)-1,3-dioxane substitués en position 2, leur préparation et leur utilisation en thérapeutique.
FR2742152B1 (fr) * 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AR012908A1 (es) 2000-11-22
EP0986552A1 (fr) 2000-03-22
CA2290695A1 (en) 1998-12-10
HUP0002166A2 (hu) 2001-06-28
WO1998055474A1 (fr) 1998-12-10
TR199903022T2 (xx) 2000-04-21
CN1265658A (zh) 2000-09-06
PL337234A1 (en) 2000-08-14
BR9810742A (pt) 2000-09-12
CO4940480A1 (es) 2000-07-24
HUP0002166A3 (en) 2002-12-28
NO995966D0 (no) 1999-12-03
KR20010013435A (ko) 2001-02-26
AU8025198A (en) 1998-12-21
IL133242A0 (en) 2001-03-19
SK166199A3 (en) 2000-06-12
EE9900560A (et) 2000-06-15
JP2002502412A (ja) 2002-01-22
NO995966L (no) 2000-02-04

Similar Documents

Publication Publication Date Title
NZ502181A (en) Triazole compounds and the use thereof as dopamine-D 3-ligands
MXPA03007248A (es) Quinazolinas como inhibidores de mmp-13.
MY125749A (en) Aralkyl and aralkylidene heterocyclic lactams and imides
PL360097A1 (en) Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
BG106013A (bg) Нови съединения и състави като протеазни инхибитори
SK86699A3 (en) Nitrogen containing heteroaromatics as factor xa inhibitors
MY119820A (en) Guanidine mimics as factor xa inhibitors
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
GB9914486D0 (en) Medicaments
IL148014A0 (en) Cell adhesion inhibitors
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
IL150651A0 (en) Nitrogen-containing cyclic compound and pharmaceutical compositions containing the same
BG106343A (bg) Амиди на карбоксилни киселини, лекарствени средства които ги съдържат, тяхното приложение и получаване
TW342385B (en) Bicyclic benzazepin, the process for their preparation and the pharmaceutical composition containing them
MX9806171A (es) Derivados 2,3-benzodiazepina y sus usos como inhibidores del receptor-ampa.
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
PL337221A1 (en) Carboxamides as antagonists of 5-ht1f
BG102015A (bg) Азациклоалканови производни, тяхното получаване и приложението им в терапията
DK0648760T3 (da) Triazinderivat og dets fremstilling og anvendelse
MX9500387A (es) Derivados del acido alfa-pirimidinil acrilico, proceso para su preparacion y composiciones fungicidas que los contienen.
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
EP1339710A4 (en) 3-oxadiazol-5-yl-1-aminoalkyl-1H-indole derivatives
DE60015146D1 (en) Serotonerge benzothiophene
TW351718B (en) Acylated aminoalkanimidazoles and -triazoles
AP2000002008A0 (en) Tetrahydroquinoline derivatives as glycine antagonists.